Aspire Advances Its Growth Trajectory with Acquisition of Cenoté Pharma Ltd.

Aspire Pharma Limited, a rapidly growing specialty generics business, continues to supplement its strong organic growth with acquisitions and strategic partnerships with the successful completion of its acquisition of Cenoté Pharma Ltd. Cenoté Pharma is a category specialist in carnitine deficiencies. Carnitine is an amino acid derivative whose insufficiency can impair the metabolism of essential tissues, such as those of the heart and muscle. The exact prevalence of systemic primary carnitine deficiency (SPCD) is unknown and varies depending on ethnicity. The acquisition of Cenoté represents the fourth acquisition Aspire has completed since being acquired by an affiliate of H.I.G. Capital in 2021, and further strengthens its specialty pharma offering.

Read the full article: Aspire Advances Its Growth Trajectory with Acquisition of Cenoté Pharma Ltd. //

Source: https://www.aspirepharma.co.uk/news/

Leave a Comment

Your email address will not be published.

Scroll to Top